Terms: = Sarcomas AND IDH1, IDP, 3417, ENSG00000138413, IDH, PICD, O75874 AND Prognosis
29 results:
1. SMARCB1-Deficient Skull Base Chondrosarcoma with 12p Duplication Presenting as Somatic-Type Malignancy Arising from Metastatic Seminoma.
Argyris PP; Challa B; Satturwar S; VanKoevering KK; Wakely PE
Head Neck Pathol; 2024 Jan; 18(1):1. PubMed ID: 38236556
[TBL] [Abstract] [Full Text] [Related]
2. Molecular Profile of Intrahepatic Cholangiocarcinoma.
Andraus W; Tustumi F; de Meira Junior JD; Pinheiro RSN; Waisberg DR; Lopes LD; Arantes RM; Rocha Santos V; de Martino RB; Carneiro D'Albuquerque LA
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203635
[TBL] [Abstract] [Full Text] [Related]
3. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
4. Expression of IL-13Rα2 and FUS in glioma: clinicopathological and prognostic correlation.
Cheng G; Wang M; Zhang X; Zhang Y
BMC Neurol; 2023 May; 23(1):185. PubMed ID: 37158824
[TBL] [Abstract] [Full Text] [Related]
5. Distinct idh1/2-associated Methylation Profile and Enrichment of
Dermawan JKT; Nafa K; Mohanty A; Xu Y; Rijo I; Casanova J; Villafania L; Benhamida J; Kelly CM; Tap WD; Boland PJ; Fabbri N; Healey JH; Ladanyi M; Lu C; Hameed M
Cancer Res Commun; 2023 Mar; 3(3):431-443. PubMed ID: 36926116
[TBL] [Abstract] [Full Text] [Related]
6. Optimizing Patient Pathways in Advanced Biliary Tract Cancers: Recent Advances and a French Perspective.
Neuzillet C; Artru P; Assenat E; Edeline J; Adhoute X; Sabourin JC; Turpin A; Coriat R; Malka D
Target Oncol; 2023 Jan; 18(1):51-76. PubMed ID: 36745342
[TBL] [Abstract] [Full Text] [Related]
7. Biology and Management of High-Grade Chondrosarcoma: An Update on Targets and Treatment Options.
Tlemsani C; Larousserie F; De Percin S; Audard V; Hadjadj D; Chen J; Biau D; Anract P; Terris B; Goldwasser F; Pasmant E; Boudou-Rouquette P
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674874
[TBL] [Abstract] [Full Text] [Related]
8. SIX4 upregulates idh1 and metabolic reprogramming to promote osteosarcoma progression.
Li B; Dang X; Duan J; Zhang G; Zhang J; Song Q
J Cell Mol Med; 2023 Jan; 27(2):259-265. PubMed ID: 36601689
[TBL] [Abstract] [Full Text] [Related]
9. A genetic model for central chondrosarcoma evolution correlates with patient outcome.
Cross W; Lyskjær I; Lesluyes T; Hargreaves S; Strobl AC; Davies C; Waise S; Hames-Fathi S; Oukrif D; Ye H; Amary F; Tirabosco R; Gerrand C; Baker T; Barnes D; Steele C; Alexandrov L; Bond G; ; Cool P; Pillay N; Van Loo P; Flanagan AM
Genome Med; 2022 Aug; 14(1):99. PubMed ID: 36042521
[TBL] [Abstract] [Full Text] [Related]
10. Periosteal chondrosarcoma: A case series in a referral center with survivorship analysis.
Pacheco M; Barra L; Gambarotti M; Magagnoli G; Sbaraglia M; Asioli S; Cocchi S; Carretta E; Frisoni T; Benini S; Dei Tos AP; Righi A
Eur J Surg Oncol; 2022 Aug; 48(8):1730-1738. PubMed ID: 35690562
[TBL] [Abstract] [Full Text] [Related]
11. DICER1 mutations in primary central nervous system tumors: new insights into histologies, mutations, and prognosis.
Liu KX; Shang HH; Cacciotti C; Everdell E; Aizer AA; Rahman R; Malinowski S; Meredith DM; Kamihara J; Wen PY; Ligon KL; Chi SN; Marcus KJ; Yeo KK; Alexandrescu S; Haas-Kogan DA
J Neurooncol; 2022 May; 157(3):499-510. PubMed ID: 35384518
[TBL] [Abstract] [Full Text] [Related]
12. Oligosarcomas, idh-mutant are distinct and aggressive.
Suwala AK; Felix M; Friedel D; Stichel D; Schrimpf D; Hinz F; Hewer E; Schweizer L; Dohmen H; Pohl U; Staszewski O; Korshunov A; Stein M; Wongsurawat T; Cheunsuacchon P; Sathornsumetee S; Koelsche C; Turner C; Le Rhun E; Mühlebner A; Schucht P; Özduman K; Ono T; Shimizu H; Prinz M; Acker T; Herold-Mende C; Kessler T; Wick W; Capper D; Wesseling P; Sahm F; von Deimling A; Hartmann C; Reuss DE
Acta Neuropathol; 2022 Feb; 143(2):263-281. PubMed ID: 34967922
[TBL] [Abstract] [Full Text] [Related]
13. Prognostic impact of idh mutations in chondrosarcoma.
Nakagawa M; Sekimizu M; Endo M; Kobayashi E; Iwata S; Fukushima S; Yoshida A; Kitabayashi I; Ichikawa H; Kawai A; Nakatani F
J Orthop Sci; 2022 Nov; 27(6):1315-1322. PubMed ID: 34531086
[TBL] [Abstract] [Full Text] [Related]
14. Circulating tumour DNA is a promising biomarker for risk stratification of central chondrosarcoma with idh1/2 and GNAS mutations.
Lyskjaer I; Davies C; Strobl AC; Hindley J; James S; Lalam RK; Cross W; Hide G; Rankin KS; Jeys L; Tirabosco R; Stevenson J; ; O'Donnell P; Cool P; Flanagan AM
Mol Oncol; 2021 Dec; 15(12):3679-3690. PubMed ID: 34528398
[TBL] [Abstract] [Full Text] [Related]
15. AHA1 upregulates idh1 and metabolic activity to promote growth and metastasis and predicts prognosis in osteosarcoma.
Zheng D; Liu W; Xie W; Huang G; Jiang Q; Yang Y; Huang J; Xing Z; Yuan M; Wei M; Li Y; Yin J; Shen J; Shi Z
Signal Transduct Target Ther; 2021 Jan; 6(1):25. PubMed ID: 33468990
[TBL] [Abstract] [Full Text] [Related]
16. Targeted Next-Generation Sequencing Identifies Molecular and Genetic Events in Dedifferentiated Chondrosarcoma.
Lucas CG; Grenert JP; Horvai A
Arch Pathol Lab Med; 2021 Aug; 145(8):1009-1017. PubMed ID: 33147331
[TBL] [Abstract] [Full Text] [Related]
17. [Primary skull base chondrosarcoma: a clinicopathological analysis].
Zhang Y; Chen XN; Ren CH; Jiang CZ; Chen YP; Lin N; Wang M; Cai SS; Li GP; Zhang S; Wang XF
Zhonghua Bing Li Xue Za Zhi; 2020 Mar; 49(3):239-243. PubMed ID: 32187895
[No Abstract] [Full Text] [Related]
18. [Osteoid-forming bone tumors : Morphology and current translational cell biology].
Roessner A; Schoeder V; Smolle M; Haybäck J
Pathologe; 2020 Mar; 41(2):123-133. PubMed ID: 32078700
[TBL] [Abstract] [Full Text] [Related]
19. Future directions in soft tissue sarcoma treatment.
Hall F; Villalobos V; Wilky B
Curr Probl Cancer; 2019 Aug; 43(4):300-307. PubMed ID: 31229264
[TBL] [Abstract] [Full Text] [Related]
20. Genetic profiling of a chondroblastoma-like osteosarcoma/malignant phosphaturic mesenchymal tumor of bone reveals a homozygous deletion of CDKN2A, intragenic deletion of DMD, and a targetable FN1-FGFR1 gene fusion.
Saba KH; Cornmark L; Rissler M; Fioretos T; Åström K; Haglund F; Rosenberg AE; Brosjö O; Nord KH
Genes Chromosomes Cancer; 2019 Oct; 58(10):731-736. PubMed ID: 31066955
[TBL] [Abstract] [Full Text] [Related]
[Next]
